Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Rating of “Moderate Buy” from Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has earned an average rating of “Moderate Buy” from the seven analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $53.29.

Several research analysts have recently issued reports on the stock. TheStreet cut shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. Benchmark reiterated a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday, April 16th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Halozyme Therapeutics in a report on Tuesday. StockNews.com upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. Finally, The Goldman Sachs Group reduced their target price on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a report on Thursday, January 18th.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total value of $416,400.00. Following the completion of the transaction, the senior vice president now owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 30,000 shares of company stock valued at $1,196,800. Company insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HALO. Rise Advisors LLC purchased a new stake in Halozyme Therapeutics in the 1st quarter worth approximately $25,000. Whittier Trust Co. bought a new position in shares of Halozyme Therapeutics during the 1st quarter valued at $27,000. Principal Securities Inc. bought a new position in shares of Halozyme Therapeutics during the 4th quarter valued at $34,000. Fidelis Capital Partners LLC acquired a new position in Halozyme Therapeutics in the 1st quarter valued at $52,000. Finally, First Horizon Advisors Inc. grew its stake in Halozyme Therapeutics by 24.5% in the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 293 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $41.21 on Wednesday. The firm’s 50 day moving average is $40.04 and its two-hundred day moving average is $37.99. Halozyme Therapeutics has a 52 week low of $29.85 and a 52 week high of $45.00. The firm has a market capitalization of $5.24 billion, a P/E ratio of 19.53, a PEG ratio of 0.47 and a beta of 1.26. The company has a current ratio of 6.64, a quick ratio of 5.50 and a debt-to-equity ratio of 17.89.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The company had revenue of $230.04 million during the quarter, compared to the consensus estimate of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. Analysts anticipate that Halozyme Therapeutics will post 3.43 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.